Vanessa M. Naimoli
Affiliations: | sanofi-aventis, St. Louis, MO, United States |
Area:
Neuroscience, psychopharmacology, latent inhibition, behavioral neuroscience, schizophrenia, MATRICS, neurodevelopment, anxiety, depression, circadian biology, immunity, comparative neuroscienceGoogle:
"Vanessa Naimoli"Mean distance: 16.82 (cluster 17)
Cross-listing: Nursing Tree
Parents
Sign in to add mentor| Alice Powers | grad student | St. John's University | |
| Mark D. Black | research scientist | sanofi-aventis | |
| Geoffrey Varty | research scientist | sanofi-aventis |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Griebel G, Pichat P, Boulay D, et al. (2016) The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophrenia. Scientific Reports. 6: 35320 |
| Naimoli V, Featherstone R, Potestio L, et al. (2015) Compound A, a novel, potent and selective mGluR2 positive allosteric modulator: III. Effects in clinically relevant translational cognition models that could be used as biomarkers F1000research. 4 |
| Rogacki N, Lopez-Grancha M, Naimoli V, et al. (2011) The neurokinin NK2 antagonist, saredutant, ameliorates stress-induced conditions without impairing cognition. Pharmacology, Biochemistry, and Behavior. 98: 405-11 |
| Overstreet DH, Naimoli VM, Griebel G. (2010) Saredutant, an NK2 receptor antagonist, has both antidepressant-like effects and synergizes with desipramine in an animal model of depression. Pharmacology, Biochemistry, and Behavior. 96: 206-10 |